The Venture Codex Logo

The Venture Codex

Overview

Biopharmaceutical company developing monoclonal antibodies.

Founded

2011

Deals ยท 12mo

0

Stage focus

Series B

Geographic focus

China

Sector focus

Biopharma
Biotechnology
Manufacturing

Investment portfolio

1rounds
NAMEDATESIZE
AnHeart Therapeutics
Dec 2021Participated
$61 MSeries B
AnHeart Therapeutics
Dec 2021Participated
$61 MSeries B
1
Items
Browse all public portfolio deals

Insights

Time horizon

View by

Deal Distribution

Innovent Biologics: 1 funding rounds are recorded in the selected participation categories.All available history.
Innovent Biologics: 1 funding rounds are recorded in the selected participation categories. All available history
Round typeLed dealsParticipated deals
Series B01

Monthly Deal Activity

Innovent Biologics: 1 deals are recorded across 59 months.All available history.
Innovent Biologics: 1 deals are recorded across 59 months. All available history
MonthDeals
Dec '211
Jan '220
Feb '220
Mar '220
Apr '220
May '220
Jun '220
Jul '220
Aug '220
Sep '220
Oct '220
Nov '220
Dec '220
Jan '230
Feb '230
Mar '230
Apr '230
May '230
Jun '230
Jul '230
Aug '230
Sep '230
Oct '230
Nov '230
Dec '230
Jan '240
Feb '240
Mar '240
Apr '240
May '240
Jun '240
Jul '240
Aug '240
Sep '240
Oct '240
Nov '240
Dec '240
Jan '250
Feb '250
Mar '250
Apr '250
May '250
Jun '250
Jul '250
Aug '250
Sep '250
Oct '250
Nov '250
Dec '250
Jan '260
Feb '260
Mar '260
Apr '260
May '260
Jun '260
Jul '260
Aug '260
Sep '260
Oct '260

Sector Breakdown

Innovent Biologics: Health & Life Sciences is the largest displayed sector by deal count (1 deals).All available history.

A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.

Innovent Biologics: Health & Life Sciences is the largest displayed sector by deal count (1 deals). All available history
SectorDeals
Health & Life Sciences1

Deal Size Distribution

Innovent Biologics: 1 rounds have a disclosed size in the displayed size bands.All available history.

Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.

Innovent Biologics: 1 rounds have a disclosed size in the displayed size bands. All available history
Round size band (USD)Deals
<$5M0
$5M-$10M0
$10M-$25M0
$25M-$50M0
$50M-$100M1
$100M-$250M0
$250M-$500M0
$500M-$1B0
$1B+0

Deals By Geography

Innovent Biologics: China has the largest recorded deal count among the displayed regions (1 deals).All available history.

Top 1 of 1 regions; European countries are grouped as Europe.

Innovent Biologics: China has the largest recorded deal count among the displayed regions (1 deals). All available history
RegionDeals
China1
Innovent Biologics: 4 co-investors are shown, with Cenova Capital sharing 1 recorded deals.All available history.

Co-Investors

Bubble size = shared deals

Click a bubble to open that fund in a new tab.

Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.

Innovent Biologics: 4 co-investors are shown, with Cenova Capital sharing 1 recorded deals. All available history
Co-investorShared deals
Cenova Capital1
Laurion Capital Management1
Octagon Capital1
Sage Partners1

Investment Strategy

Innovent Biologics: Led accounts for 0% and participating for 100% of round participation.All available history.
Innovent Biologics: Led accounts for 0% and participating for 100% of round participation. All available history
CategoryDeals (count)Share (%)
Led00%
Participating1100%
Innovent Biologics: Single-lead accounts for 0% and co-led for 0% of lead dynamics.All available history.
Innovent Biologics: Single-lead accounts for 0% and co-led for 0% of lead dynamics. All available history
CategoryDeals (count)Share (%)
Single-lead00%
Co-led00%

Lead dynamics requires at least one led deal in this range

Team

Joanne Sun

VP Translational Medicine

Michael Yu

Co-founder, CEO and President

Min Liu

Chief Commercial Officer

Nageatte Ibrahim

Oncology Chief Medical Officer

Qinwei Zhou

Chief Operation Officer

Ronald Ede

Chief Financial Officer

Samuel Zhang

Chief Business Officer